Who owns CNS Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CNSP from SEC Form 13F filings across 11 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 11 institutions disclosed 280,434 shares of CNS Pharmaceuticals, Inc. worth $1.3M — about 4.1% of shares outstanding; the largest disclosed holder is Ikarian Capital, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
11
13F holders
$1.3M
value, 2026 filers
4.1%
of shares outstanding (280,434 sh)
4
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of CNSP's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 135,830 | $649,267 | 0.1% | 2% | +196.4% |
| 2 | ADAR1 Capital Management, LLCNEW | 70,000 | $334,600 | 0.0% | 1% | new |
| 3 | Stonepine Capital Management, LLC | 41,573 | $198,719 | 0.1% | 0.6% | -31.8% |
| 4 | BOOTHBAY FUND MANAGEMENT, LLC | 13,524 | $64,645 | 0.0% | 0.2% | 0.0% |
| 5 | VANGUARD FIDUCIARY TRUST CONEW | 10,226 | $48,880 | 0.0% | 0.1% | new |
| 6 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 6,993 | $33,427 | 0.0% | 0.1% | new |
| 7 | UBS Group AG | 1,461 | $6,983 | 0.0% | 0% | +100.4% |
| 8 | Tower Research Capital LLC (TRC) | 799 | $3,819 | 0.0% | 0% | -39.0% |
| 9 | BARCLAYS PLCNEW | 19 | $91 | 0.0% | 0% | new |
| 10 | BARRETT & COMPANY, INC. | 8 | $38 | 0.0% | 0% | 0.0% |
| 11 | DANSKE BANK A/S | 1 | $5 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.